ALMS - NASDAQ

Alumis Inc. Common Stock

ALMS·NASDAQ

$20.08

-1.2%

HealthcareBiotechnology

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$2.48B

EPS-2.8600

P/E Ratio-7.02

Earnings Date08/12/2026

alms

Gross Profit

Last Annual Value

20.55M

3-Year CAGR

338%

5-Year CAGR

143%

10-Year CAGR

56%

Adjust for Inflation

Alumis Inc. Common Stock Competitors Analysis of Gross Profit

ALMS · NASDAQ

Company	Gross Profit	CAGR 3Y	CAGR 5Y	CAGR 10Y
Alumis Inc. Common Stock NASDAQ:ALMS	20.55M	N/A	N/A	N/A
Eton Pharmaceuticals, Inc. NASDAQ:ETON	42.74M	26.6%	17.3%	N/A
Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA	-5.00M	N/A	N/A	N/A
Fulcrum Therapeutics, Inc. NASDAQ:FULC	-1.39M	N/A	N/A	N/A
Lexicon Pharmaceuticals, Inc. NASDAQ:LXRX	49.53M	N/A	N/A	N/A
RAPT Therapeutics, Inc. NASDAQ:RAPT	0.00	N/A	N/A	N/A
Ocugen, Inc. NASDAQ:OCGN	2.02M	-27.6%	N/A	N/A
Lineage Cell Therapeutics, Inc. AMEX:LCTX	13.71M	18.3%	40.9%	21.9%
Omeros Corporation NASDAQ:OMER	0.00	N/A	N/A	N/A

Alumis Inc. Common Stock Fair Value Envelope

ALMS · NASDAQ

Our analysis suggests that ALMS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $20.08, this represents a potential HIDDEN relative to our calculated worth for Alumis Inc. Common Stock.

HIDDEN

Intrinsic Value

Current Price: $20.08

Related Guides

Blog Categories

Continue your ALMS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.